Examkin

Question

Difficulty: HardDepressive Disorders

A 35-year-old woman is brought to the clinic by her husband for a follow-up appointment. Two weeks ago, she was prescribed sertraline 50 mg daily for a 2-month history of pervasive sadness, sleeping 12 hours a day, a heavy sensation in her extremities, and a 10-lb weight gain following the sudden death of her father. Today, she reports no improvement in her mood and asks to stop the antidepressant because "two weeks is long enough to know it is not working."

She has a history of a pituitary microadenoma treated with transsphenoidal resection 3 years ago, for which she takes levothyroxine. She also takes a daily over-the-counter St. John's wort supplement. Upon further questioning, her husband notes that during college, the patient had a distinct 6-day period where she slept only 2 hours a night, spoke extremely rapidly, and maxed out her credit cards. She also mentions hearing her deceased father's voice calling her name once a few days ago.

Vital signs are within normal limits. Laboratory studies show:

TestResultReference Range
Thyroid-stimulating hormone (TSH)0.2 µU/mL0.4-4.0 µU/mL
Free thyroxine (T4)0.6 ng/dL0.9-1.7 ng/dL

Which of the following is the most appropriate next step in management?

  1. Cross-taper sertraline to quetiapine and discontinue St. John's wortAnswer
  2. B
    Increase the sertraline dosage to 100 mg daily
  3. C
    Continue the current regimen to allow a full 6-week therapeutic trial
  4. D
    Discontinue sertraline and decrease the levothyroxine dosage
  5. E
    Initiate haloperidol monotherapy for new-onset schizoaffective disorder

Answer

Cross-taper sertraline to quetiapine and discontinue St. John's wort
The patient's presentation of a major depressive episode combined with a history of a distinct hypomanic episode (lasting at least 4 days with decreased need for sleep, rapid speech, and impulsivity) establishes a diagnosis of Bipolar II disorder. In bipolar depression, SSRI monotherapy is contraindicated due to the risk of inducing a manic switch. The most appropriate pharmacotherapy includes withdrawing the SSRI and initiating a medication approved for bipolar depression, such as quetiapine. Furthermore, St. John's wort must be discontinued because its concurrent use with an SSRI poses a significant risk for serotonin syndrome, and as a CYP3A4 inducer, it would subtherapeutically lower quetiapine levels.

Step-by-Step Solution

1
Evaluate the patient's psychiatric history to establish a correct diagnosis.
The patient has a current major depressive episode with atypical features, plus a history of a 6-day hypomanic episode (decreased sleep, rapid speech, impulsivity). This confirms a diagnosis of Bipolar II disorder.
Differentiating unipolar from bipolar depression is critical before managing antidepressant therapy.
2
Assess the safety of the current pharmacologic regimen.
The patient is on an SSRI (sertraline) and St. John's wort. This combination poses a high risk for serotonin syndrome.
Both agents possess strong serotonergic activity and must not be used concurrently.
3
Determine the appropriate psychopharmacological intervention.
SSRI monotherapy is contraindicated in bipolar depression due to the risk of mood destabilization. A transition to an approved bipolar depression agent (e.g., quetiapine, lurasidone) is required.
Although the patient wants to stop the drug prematurely due to 'lack of efficacy' at 2 weeks, stopping it is actually the correct medical decision due to the bipolar diagnosis and interaction risks.
4
Interpret the thyroid function tests in the context of her surgical history.
Both TSH and Free T4 are low. In a patient with prior transsphenoidal resection, this indicates central hypothyroidism where she is under-replaced.
TSH is unreliable in pituitary disease; the low Free T4 dictates management (she needs more levothyroxine, not less).

Key Concept

Patients presenting with a depressive episode must be screened for a history of mania/hypomania; Bipolar depression requires mood-stabilizing agents (e.g., quetiapine) rather than SSRI monotherapy, and concurrent use of multiple serotonergic agents (like St. John's wort) must be avoided.
Estimated Time:1m 30s
Rate this question

Topics

Depressive Disorders

More questions from this topic